再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症

智通财经

03-11

智通财经APP获悉，日前，再生元(REGN.US)和赛诺菲(SNY.US)在2025年美国皮肤科学会(AAD)年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent(dupilumab)在治疗中重度大疱性类天疱疮(BP)成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请(sBLA)已经获得FDA授予的优先审评资格，有望在今年年中获批。

Dupixent是一种全人源化单克隆抗体，能够抑制白细胞介素4(IL-4)和白细胞介素13(IL-13)信号通路。它已在全球60多个国家和地区获得一种或多种适应症的监管批准，包括特应性皮炎、哮喘、伴鼻息肉的慢性鼻窦炎、嗜酸性食管炎、结节性瘙痒症、慢性自发性荨麻疹及慢性阻塞性肺病。全球有超过100万名患者正在接受Dupixent治疗。

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2518464787"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518464787\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518464787?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-11 07:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518464787","market":"sh","top_or_hot":-1,"title":"再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症","media":"智通财经","content":"<html><body><p>智通财经APP获悉，日前，再生元(REGN.US)和<a href=\"https://laohu8.com/S/0O59.UK\">赛诺菲</a>(SNY.US)在2025年美国皮肤科学会(AAD)年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent(dupilumab)在治疗中重度大疱性类天疱疮(BP)成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请(sBLA)已经获得FDA授予的优先审评资格，有望在今年年中获批。</p><p>Dupixent是一种全人源化单克隆抗体，能够抑制白细胞介素4(IL-4)和白细胞介素13(IL-13)信号通路。它已在全球60多个国家和地区获得一种或多种适应症的监管批准，包括特应性皮炎、哮喘、伴鼻息肉的慢性鼻窦炎、嗜酸性食管炎、结节性瘙痒症、慢性自发性荨麻疹及慢性阻塞性肺病。全球有超过100万名患者正在接受Dupixent治疗。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n再生元(REGN.US)和赛诺菲(SNY.US)重磅抗炎药年中有望再添新适应症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-11 07:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1260115.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，日前，再生元(REGN.US)和赛诺菲(SNY.US)在2025年美国皮肤科学会(AAD)年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent(dupilumab)在治疗中重度大疱性类天疱疮(BP)成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1260115.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2362541513.USD","symbol_name":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1260115.html","article_id":"2518464787","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518464787","pubTimestamp":1741649927,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，日前，再生元和赛诺菲在2025年美国皮肤科学会年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent在治疗中重度大疱性类天疱疮成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请已经获得FDA授予的优先审评资格，有望在今年年中获批。全球有超过100万名患者正在接受Dupixent治疗。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4007":"制药","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SNY":"赛诺菲安万特","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","REGN":"再生元制药公司","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Regeneron (REGN.US) and Sanofi (SNY.US) blockbuster anti-inflammatory drugs are expected to add new indications mid-year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1,"SNY":1},"content_text":"智通财经APP获悉，日前，再生元(REGN.US)和赛诺菲(SNY.US)在2025年美国皮肤科学会(AAD)年会上，公布了关键性2/3期临床试验ADEPT的积极结果。该试验评估重磅疗法Dupixent(dupilumab)在治疗中重度大疱性类天疱疮(BP)成人患者时的疗效和安全性。ADEPT试验达到了所有主要及关键次要终点，接受Dupixent治疗的患者获得持久缓解的比例是安慰剂组的5倍。Dupixent治疗BP的补充生物制品许可申请(sBLA)已经获得FDA授予的优先审评资格，有望在今年年中获批。Dupixent是一种全人源化单克隆抗体，能够抑制白细胞介素4(IL-4)和白细胞介素13(IL-13)信号通路。它已在全球60多个国家和地区获得一种或多种适应症的监管批准，包括特应性皮炎、哮喘、伴鼻息肉的慢性鼻窦炎、嗜酸性食管炎、结节性瘙痒症、慢性自发性荨麻疹及慢性阻塞性肺病。全球有超过100万名患者正在接受Dupixent治疗。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}